Coherus Biosciences Inc
CHRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$172.6M
Close$
$-0.30
120.2% downside
Current Fair Value
120.2% downsideOvervalued by 120.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $172.60 Million |
|---|---|
| Enterprise Value | $111.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 0.98 |
| Outstanding Shares | 136,398,303 |
Return
| Return on Equity | -192.90% |
|---|---|
| Return on Assets | -57.01% |
| Return on Invested Capital | -132.02% |
Valuation & Multiples
| P/E Ratio | -1.1 |
|---|---|
| PEG | 3.34 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.38 |
| Enterprise Value to EBIT | -0.63 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.49 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$23.01 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$14.41 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 485.91% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.70%▼ 42.76% |
|---|---|
| Total Invested | $1.33M▼ 98.67% |
| Investors Holding | 26▼ 135.00% |
ESG Score
No data
About Coherus Biosciences Inc
CEO: Dennis Lanfear